ProCE Banner Activity

How I Manage Ibrutinib-Refractory Patients With CLL Without Del(17p)

Clinical Thought
In the past few years, striking progress has been made in the treatment of ibrutinib-refractory CLL. Read my thoughts on how these promising developments might be applied in your practice.

Released: April 13, 2017

Expiration: April 12, 2018

No longer available for credit.

Share

Faculty

Farrukh Awan

Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Genentech Roche Virology

Janssen Pharmacyclics

Pharmacyclics Inc

Faculty Disclosure

Primary Author

Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Farrukh Awan, MD, MS, has disclosed that he has received consulting fees from Gilead Sciences and Pharmacyclics.